Skip to main content

Peer Review reports

From: Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Original Submission
30 Jun 2023 Submitted Original manuscript
19 Sep 2023 Reviewed Reviewer Report
20 Sep 2023 Reviewed Reviewer Report
7 Oct 2023 Author responded Author comments - Dehua Zhao
15 Oct 2023 Reviewed Reviewer Report
28 Oct 2023 Author responded Author comments - Dehua Zhao
Resubmission - Version 2
7 Oct 2023 Submitted Manuscript version 2
Publishing
9 Feb 2024 Editorially accepted
23 Feb 2024 Article published 10.1186/s40360-024-00741-x

You can find further information about peer review here.

Back to article page